Clinical trial
Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on…
NCT00287820 · Nathan Kline Institute for Psychiatric Research, Other · Completed
Key facts
| NCT number | NCT00287820 |
|---|---|
| Title | Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism |
| Official title | Independent Investigator Grant Study-Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism |
| Lead sponsor | Nathan Kline Institute for Psychiatric Research, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia |
| Intervention type | Drug |
| Interventions | Olanzapine, olanzapine, risperidone |
| Enrollment | 46 |
| Start date | Feb 1, 2004 |
| Completion | Sep 1, 2007 |
| First posted | Feb 7, 2006 |
| Last update posted | Jul 25, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: